Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis
International Urology and Nephrology · 2026
DOI: 10.1007/s11255-026-05003-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urology and Nephrology, 2026. Verfasst von Kieran Sandhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Services, Peter MacCallum Cancer Centre, Parkville, Australia. kieran.s11@outlook.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists, Antineoplastic Agents, Hormonal. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Androgen deprivation therapy (ADT) has been pivotal in advanced prostate cancer (PCa) for decades. The introduction of androgen-receptor pathway inhibitors (ARPIs) has transformed treatment paradigms. However, their real-world adoption over time has not been comprehensively characterised. We examined prescribing trends for androgen-directed therapies in Australia over a 29-year period. METHODS: A retrospective population-based analysis of Pharmaceutical Benefits Scheme (PBS) dispensing data (1996-2024) was performed. PBS-listed anti-androgen therapies-luteinising hormone-releasing hormone (LHRH) agonists (goserelin, leuprorelin, triptorelin), combined androgen blockage (CAB) (LHRH + bicalutamide), ARPIs (enzalutamide, apalutamide, darolutamide, abiraterone)-were included. Annual prescription counts were standardised per 100,000 men. Outcomes included temporal trends, proportional contribution of each drug class, and the effect of ARPI introduction using interrupted time-series (ITS) analysis. RESULTS: Anti-androgen prescriptions rose from 146 to 228,707 between 1996 and 2024, respectively. LHRH monotherapy accounted for > 94% of prescriptions prior to ARPI approval, declining to 51.61% in 2024 despite continued absolute growth (+ 65.16 prescriptions/100,000/year, p < 0.0001). ARPIs expanded following PBS listing, increasing from 2.44% in 2013 to 47.28% in 2024 (+ 131.9 prescriptions/100,000/year, p < 0.0001). ITS modelling demonstrated a significant immediate level increase of + 9.85 percentage points (p < 0.0001) and sustained a post-intervention slope increase of + 3.04 percentage points per year (p < 0.0001) following ARPI introduction, closely mirroring observed proportional and absolute growth 3.44-47.28% between 2013 and 2024, respectively. CONCLUSION: Australia has transitioned from predominately LHRH-based therapy to widespread use of ARPIs. Health-system structures enabling timely clinical access appears pivotal to the rapid and equitable diffusion of high-value androgen-targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Services, Peter MacCallum Cancer Centre, Parkville, Australia. kieran.s11@outlook.com.
- Department of Urology, Royal Melbourne Hospital, Melbourne, Australia.
- Department of Pharmacy, Canberra Hospital, Garran, Australia.
- Department of Pharmacy, Royal Melbourne Hospital, Melbourne, Australia.
- Division of Cancer Services, Peter MacCallum Cancer Centre, Parkville, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Zitieren
APA
Sandhu, K., Wells, C., Newton, M. M. H., Murphy, D. G., Lawrentschuk, N., & Perera, M. L. (2026). Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis. International Urology and Nephrology. https://doi.org/10.1007/s11255-026-05003-9
Vancouver
Sandhu K, Wells C, Newton MMH, Murphy DG, Lawrentschuk N, Perera ML. Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis. International Urology and Nephrology. 2026. doi:10.1007/s11255-026-05003-9
BibTeX
@article{Sandhu2026,
author = {Sandhu, Kieran and Wells, Cynthia and Newton, Matilda M H and Murphy, Declan G and Lawrentschuk, Nathan and Perera, Marlon L},
title = {Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis},
journal = {International Urology and Nephrology},
year = {2026},
doi = {10.1007/s11255-026-05003-9}
}
EUVIMED